Sign in or create an account to add this stock to your watchlist.
About Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CLDX
CUSIP15117B10
Phone908-200-7500
Debt
Debt-to-Equity RatioN/A
Current Ratio5.45
Quick Ratio5.45
Price-To-Earnings
Trailing P/E Ratio-0.84
Forward P/E Ratio-0.99
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.74 million
Price / Sales7.56
Cash FlowN/A
Price / CashN/A
Book Value$0.94 per share
Price / Book0.71
Profitability
EPS (Most Recent Fiscal Year)($0.80)
Net Income$-93,030,000.00
Net Margins-1,157.96%
Return on Equity-47.36%
Return on Assets-33.16%
Miscellaneous
Employees197
Outstanding Shares143,390,000
Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions
What is Celldex Therapeutics' stock symbol?
Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."
How were Celldex Therapeutics' earnings last quarter?
Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its earnings results on Wednesday, March, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.08. The biopharmaceutical company earned $3.50 million during the quarter, compared to analysts' expectations of $1.49 million. Celldex Therapeutics had a negative return on equity of 47.36% and a negative net margin of 1,157.96%. Celldex Therapeutics's revenue for the quarter was up 87.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.30) EPS. View Celldex Therapeutics' Earnings History.
When is Celldex Therapeutics' next earnings date?
What price target have analysts set for CLDX?
6 brokerages have issued 12-month price objectives for Celldex Therapeutics' shares. Their forecasts range from $2.00 to $10.00. On average, they expect Celldex Therapeutics' stock price to reach $4.50 in the next year. View Analyst Ratings for Celldex Therapeutics.
What are Wall Street analysts saying about Celldex Therapeutics stock?
Here are some recent quotes from research analysts about Celldex Therapeutics stock:
- 1. Cowen Inc analysts commented, "We spoke with the company who clarified that it remains comfortable on what it has said about dosing for VY-AADC. We believe eventual dosing for the pivotal Phase 2/3 trial could come in between the doses used in the initial Phase 1b, i.e., between 1.5×10 12 to 4.5×10 12 vg in 900µl/putamen. Separately, VYGR has submitted a 510(k) device application in Mar-18 for its own Guide (V-TAG) that could serve as an alternative to the ClearPoint magnetic resonance imaging (MRI) compatible device used in the procedures so far; 10-K expected a V- TAG filing in 1H18. As such, we view this pullback as a particularly good opportunity to BUY this volatile stock." (5/10/2018)
- 2. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline received a major setback with failure of its lead pipeline candidate, glembatumumab vedotin, in breast cancer study. Following the failure, the company discontinued development of the candidate across all indications. With no approved products, further pipeline setbacks will severely impact Celldex. Celldex is now focusing on other promising candidates in its pipeline including varlilumab. Meanwhile, the Kolltan acquisition added some interesting candidates to the company’s pipeline. However, Celldex depends entirely on product development, licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Also, shares of the company have underperformed the industry so far this year. Loss estimates have narrowed ahead of Q1 results. Clovis has a positive record of earnings surprises in the recent quarters." (5/8/2018)
- 3. Cantor Fitzgerald analysts commented, "Glemba is a Miss. The METRIC trial evaluating metastatic TNBC patients that overexpress gpNMB versus capecitibine did not achieve statistical significance, with glemba-treated patients experiencing PFS of 2.7 months versus 2.6 months for capecitibine, p=0.76. Additionally, significance was not achieved for key secondary endpoints of OR (overall response), DoR (Duration of Response) or OS (Overall Survival)." (4/17/2018)
Are investors shorting Celldex Therapeutics?
Celldex Therapeutics saw a decrease in short interest in the month of April. As of April 30th, there was short interest totalling 8,111,748 shares, a decrease of 22.3% from the April 13th total of 10,445,637 shares. Based on an average trading volume of 8,499,808 shares, the short-interest ratio is presently 1.0 days. Currently, 5.7% of the shares of the company are sold short.
Who are some of Celldex Therapeutics' key competitors?
Some companies that are related to Celldex Therapeutics include Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Vermillion (VRML), Akers Biosciences (AKER), ImmuCell (ICCC), Achieve Life Sciences (ACHV), GeneNews (GNWSF), ARCA biopharma (ABIO), FluoroPharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).
Who are Celldex Therapeutics' key executives?
Celldex Therapeutics' management team includes the folowing people:
- Mr. Anthony S. Marucci, Founder, Pres, CEO & Director (Age 56)
- Dr. Tibor Keler Ph.D., Founder, Chief Scientific Officer and Exec. VP (Age 59)
- Ms. Elizabeth Crowley, Chief Product Devel. Officer and Sr. VP (Age 46)
- Mr. Sam Martin, Sr. VP, CFO, Principal Accounting Officer & Treasurer
- Ms. Sarah Cavanaugh, Sr. VP of Corp. Affairs & Admin.
Has Celldex Therapeutics been receiving favorable news coverage?
News stories about CLDX stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.18 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 44.79 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Celldex Therapeutics' major shareholders?
Celldex Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.04%), Dimensional Fund Advisors LP (2.91%), TSP Capital Management Group LLC (1.00%), JPMorgan Chase & Co. (0.69%), State of Wisconsin Investment Board (0.51%) and Schwab Charles Investment Management Inc. (0.40%). View Institutional Ownership Trends for Celldex Therapeutics.
Which major investors are selling Celldex Therapeutics stock?
Which major investors are buying Celldex Therapeutics stock?
How do I buy shares of Celldex Therapeutics?
Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celldex Therapeutics' stock price today?
One share of CLDX stock can currently be purchased for approximately $0.6716.
How big of a company is Celldex Therapeutics?
Celldex Therapeutics has a market capitalization of $96.30 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-93,030,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Celldex Therapeutics employs 197 workers across the globe.
How can I contact Celldex Therapeutics?
Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]
MarketBeat Community Rating for Celldex Therapeutics (CLDX)
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe CLDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Celldex Therapeutics (NASDAQ:CLDX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Celldex Therapeutics in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 570.04%. The high price target for CLDX is $10.00 and the low price target for CLDX is $2.00. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Hold | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.43 | 2.83 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.50 | $4.50 | $8.1250 | $7.50 |
| Price Target Upside: | 570.04% upside | 491.33% upside | 237.14% upside | 172.73% upside |
Celldex Therapeutics (NASDAQ:CLDX) Consensus Price Target History
Celldex Therapeutics (NASDAQ:CLDX) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Celldex Therapeutics (NASDAQ:CLDX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Celldex Therapeutics (NASDAQ CLDX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 54.82%
Celldex Therapeutics (NASDAQ CLDX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/2/2016 | Tibor Keler | VP | Buy | 3,000 | $3.32 | $9,960.00 | 18,868 |  |
| 11/23/2015 | Avery W. Catlin | CFO | Sell | 25,000 | $18.00 | $450,000.00 | 35,109 | |
| 8/25/2015 | Larry Ellberger | Director | Buy | 5,000 | $14.00 | $70,000.00 | 53,500 | |
| 8/20/2015 | Larry Ellberger | Director | Buy | 5,000 | $15.00 | $75,000.00 | 48,500 | |
| 8/18/2015 | Larry Ellberger | Director | Buy | 5,000 | $15.95 | $79,750.00 | 43,500 | |
| 8/13/2015 | Anthony S Marucci | CEO | Buy | 5,800 | $16.81 | $97,498.00 | | |
| 8/13/2015 | Larry Ellberger | Director | Buy | 5,000 | $16.59 | $82,950.00 | | |
| 6/15/2015 | Avery W Catlin | CFO | Sell | 25,000 | $24.59 | $614,750.00 | | |
| 12/6/2013 | Avery Catlin | CFO | Sell | 183,333 | $24.50 | $4,491,658.50 | 14,109 | |
| 12/6/2013 | Larry Ellberger | Director | Sell | 17,728 | $24.50 | $434,336.00 | 25,000 | |
(Data available from 1/1/2013 forward)
Celldex Therapeutics (NASDAQ CLDX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Celldex (CLDX) Announces Presentations at ASCO
www.streetinsider.com - May 17 at 5:41 PM |
 | Celldex Therapeutics (CLDX) Given a $2.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 17 at 3:09 PM |
 | Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 16 at 5:11 PM |
| May Insights Into Healthcare Stocks: Celldex Therapeutics Inc (NASDAQ:CLDX)
finance.yahoo.com - May 15 at 5:28 PM |
| Contrasting Idexx Laboratories (IDXX) & Celldex Therapeutics (CLDX)
www.americanbankingnews.com - May 13 at 9:47 AM |
| Celldex Therapeutics, Inc. (CLDX) Sees Large Drop in Short Interest
www.americanbankingnews.com - May 12 at 2:10 AM |
 | Celldex Trying To Regroup With Its Early-Stage Assets
seekingalpha.com - May 11 at 5:24 PM |
 | Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down
www.zacks.com - May 11 at 9:10 AM |
| Zacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $2.03 Million
www.americanbankingnews.com - May 11 at 2:04 AM |
| Celldex Therapeutics (CLDX) Given Hold Rating at Cowen
www.americanbankingnews.com - May 10 at 9:39 PM |
| Celldex (CLDX) Q1 Loss Narrower, Revenues Beat, Shares Down
finance.yahoo.com - May 10 at 5:27 PM |
| Celldex Therapeutics Moves Forward After Glemba Clinical Failure
finance.yahoo.com - May 10 at 5:27 PM |
 | BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84
www.reuters.com - May 10 at 8:52 AM |
| Celldex: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:52 AM |
| Celldex Provides Corporate Update and Reports First Quarter 2018 Results
finance.yahoo.com - May 10 at 8:52 AM |
| Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 9 at 9:14 PM |
| Celldex Therapeutics (CLDX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 8 at 3:23 PM |
| Celldex Therapeutics (CLDX) Lifted to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 10:19 PM |
| What's in Store for Celldex (CLDX) This Earnings Season?
finance.yahoo.com - May 3 at 5:02 PM |
| Contrasting Celldex Therapeutics (CLDX) & Oxford Immunotec Global (OXFD)
www.americanbankingnews.com - May 3 at 3:10 AM |
| Form 4 Celldex Therapeutics, For: May 01 Filed by: McMahon Gerald PhD
www.streetinsider.com - May 2 at 5:12 PM |
| Celldex Therapeutics (CLDX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 8:54 AM |
| Celldex Therapeutics, Inc. (CLDX) Short Interest Up 14.7% in April
www.americanbankingnews.com - April 27 at 1:24 AM |
| Biotech Analysis Central Pharma News: Takeda Raises Shire Bid, Daiichi Fails DMD Trial, Celldex Cuts 20% Of Workforce
seekingalpha.com - April 26 at 5:00 PM |
| Celldex Therapeutics, Inc. (CLDX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 26 at 1:27 PM |
| BRIEF-Celldex Therapeutics Approves Workforce Reduction
www.reuters.com - April 24 at 5:16 PM |
| Brokerages Anticipate Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $2.03 Million
www.americanbankingnews.com - April 24 at 3:04 AM |
| Is It Game Over for Celldex?
finance.yahoo.com - April 23 at 4:56 PM |
| Cantor Fitzgerald Brokers Reduce Earnings Estimates for Celldex Therapeutics, Inc. (CLDX)
www.americanbankingnews.com - April 23 at 2:48 AM |
| Celldex Therapeutics, Inc. (CLDX) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - April 22 at 11:15 AM |
| Celldex (CLDX) Says Data from Multiple Programs Presented at AACR
www.streetinsider.com - April 21 at 5:00 PM |
 | Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting ...
globenewswire.com - April 20 at 5:03 PM |
| 3 Things In Biotech, April 18: Bristol Plows Ahead, Celldex Flops, Alkermes Gets A Surprise
seekingalpha.com - April 19 at 8:42 AM |
| Jefferies Group Weighs in on Celldex Therapeutics, Inc.'s FY2021 Earnings (CLDX)
www.americanbankingnews.com - April 19 at 7:38 AM |
| Celldex Tumbles On Phase 2 Trial Failure; Is There Any Value Left?
seekingalpha.com - April 18 at 5:22 PM |
| Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
finance.yahoo.com - April 17 at 5:33 PM |
| Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
finance.yahoo.com - April 17 at 5:33 PM |
| Celldex Therapeutics (CLDX) Stock Rating Lowered by Cantor Fitzgerald
www.americanbankingnews.com - April 17 at 11:04 AM |
| Celldex Therapeutics (CLDX) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - April 16 at 8:40 PM |
| CLDX Apr 2018 5.000 put
finance.yahoo.com - April 16 at 5:02 PM |
 | Why Celldex Therapeutics Is Getting Crushed
247wallst.com - April 16 at 5:02 PM |
| Why Celldex Therapeutics Stock Is Cratering Today
finance.yahoo.com - April 16 at 5:02 PM |
| Cowen Downgrades Celldex Therapeutics (CLDX) to Market Perform
www.americanbankingnews.com - April 16 at 1:21 PM |
| Celldex Therapeutics (CLDX) Downgraded by HC Wainwright to Buy
www.americanbankingnews.com - April 16 at 12:05 PM |
| Celldex's lead candidate flunks breast cancer study; shares down 51% premarket
seekingalpha.com - April 16 at 8:39 AM |
 | Celldex To Discontinue Glembatumumab Vedotin Program Across All Indications
www.nasdaq.com - April 16 at 8:39 AM |
| Celldex's stock plummets toward record low after failed drug study
finance.yahoo.com - April 16 at 8:39 AM |
| Celldex’s METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint
finance.yahoo.com - April 16 at 8:39 AM |
| Celldex Therapeutics (CLDX) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - April 14 at 3:38 PM |
| Celldex Therapeutics (CLDX) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - April 14 at 7:21 AM |
Celldex Therapeutics (NASDAQ:CLDX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Celldex Therapeutics (NASDAQ:CLDX) Income Statement, Balance Sheet and Cash Flow Statement
Celldex Therapeutics (NASDAQ CLDX) Stock Chart for Sunday, May, 20, 2018
Loading chart…
